Multiplex analysis of anti-apoptotic BCL2 family and caspase 3 activation by microbead arrays.
We have developed a multiplex assay to measure the expression of anti-apoptotic proteins and caspase 3 activation using the Luminex platform. In this report, we show three applications for this assay. First, we used this assay to identify biomarkers for BCL2 inhibitors to obtain a quantitative measure of expression of anti-apoptotic proteins (BCL2, BCLxL, and MCL1) in a panel of cell lines and correlated their response to BCL2/BCLxL inhibitor, ABT-263 (navitoclax). Second, we used this assay to monitor the change of MCL1 protein expression and induction of active caspase 3 after treatment with cyclin-dependent kinase inhibitor flavopiridol. Finally, we used this assay to screen for small molecules that decrease MCL1 protein and identified new combinations with ABT-263. This method provides a quick and convenient way to measure basal expression of the anti-apoptotic proteins and monitor expression change upon drug treatment. It is also applicable for high-throughput screening for compounds that decrease the expression of these anti-apoptotic proteins.